904P ACCURACY: A phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut): Results of 6-mg cohort - Ho, A.L.; Bowles, D.W.; Even, C.; Hao, D.; Kang, H.; Metcalf, R.; Muzaffar, J.; Oliva, M.; Perez, C.A.; Popovtzer, A.; Rodriguez, C.P.; Stemmer, S.M.; et al. (Annals of oncology, 2021)